Weekly Digest – February 2025 Weekly Digest – February 2025 14 Feb 2025: 1st Trop-2 ADC Trodelvy expands indication to metastatic HR+/HER2- breast cancer Trodelvy (Sacituzumab govitecan) received expanded approval in Korea to treat metastatic HR+/HER2- breast cancer resistant to […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Corbus posts first US data on challenger to Pfizer’s ADC Padcev Corbus Pharmaceuticals’ western trial of its ADC showed a 27% response rate, aligning with prior Chinese […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC) Radiance Biopharma has signed an exclusive license agreement with CSPC Megalith for the development and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities Sonnet BioTherapeutics announced its ADC platform, leveraging its FHAB domain for flexible payload capacity and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 20 Feb 2025: Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer Myris Therapeutics, formerly BioHybrid Solutions, has emerged from stealth with a focus […]
Weekly Digest – February 2025 Weekly Digest – February 2025 12 Feb 2025: U.S. FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of relapsed/refractory diffuse large B-cell lymphoma The FDA approved ADCETRIS (Brentuximab vedotin) for treating adult patients with […]
Weekly Digest – February 2025 Weekly Digest – February 2025 12 Feb 2025: OnCusp Therapeutics receives FDA Fast Track Designation for CUSP06 for the treatment of platinum-resistant ovarian cancer The FDA granted Fast Track Designation to OnCusp Therapeutics’ lead program, […]
Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: DAAN Biotherapeutics signs antibody exclusive licensing agreement with LigaChem Biosciences for ADC therapeutic development DAAN Biotherapeutics signed an exclusive licensing deal with LigaChem Biosciences for a tumor-targeting […]
Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: IDEAYA announces further Gilead sciences clinical study collaboration evaluating combination of Trodelvy and IDE397 in MTAP-deletion NSCLC The combination targets two complementary mechanisms in MTAP-deletion solid tumors, […]
Weekly Digest – February 2025 Weekly Digest – February 2025 11 February 2025: Ellipses In-Licences first in class novel Immuno-oncology agent with potential as a next generation checkpoint inhibitor Ellipses Pharma will develop GENA-104 (EP0089), a first-in-class monoclonal antibody targeting […]
